EUCTR2015-002731-17-HU进行中（未招募）1 期
A Phase 1b-2, Open-Label, Dose Escalation and Expansion Study Evaluatingthe Safety and Efficacy of Entospletinib (ENTO [GS-9973]) combined with Vincristine (VCR) in Adult Subjects with Relapsed or Refractory B-cell Non- Hodgkin Lymphoma (NHL)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 94
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Subjects = 18 years of age
- •2) Measurable disease by computed tomograph (CT)/ and/or positron- emission tomography CT (PET-CT)
- •3) A) Dose Escalation Stage: Confirmed Diagnosis of relapsed or refractory Non-Hodgkin Lymphoma (NHL) treated with prior treatment for lymphoid malignancy comprising of at least 1 regimen containing a therapeutic anti-CD20 antibody (eg, rituximab, ofatumumab, GA-101) and at least 2 prior combination chemotherapy
- •regimens or autologous stem cell transplant, or treated with 1 prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician
- •B) Dose Expansion Cohorts:
- •i) Expansion Cohort A: Diagnosis of relapsed or refractory DLBCL
- •treated with prior
- •treatment for lymphoid malignancy comprising of at least 1 regimen containing a therapeutic anti-CD20 antibody (eg, rituximab, ofatumumab, GA-101) and at least 2 prior combination chemotherapy regimens or autologous stem cell transplant, or treated with 1 prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician.
- •ii) Expansion Cohort B: Diagnosis of relapsed or refractory B-cell NHL (other than DLBCL) treated with prior treatment for lymphoid malignancy comprising of at least 1 regimen
- •containing a therapeutic anti-CD20 antibody (eg, rituximab, ofatumumab, GA-101) and at least 2 prior combination chemotherapy regimens or autologous stem cell transplant, or treated with 1 prior combination chemotherapy regimen in patients without an approved second-line therapy option, requiring treatment in the opinion of the treating physician
- •4) Eastern Cooperative Oncology Group (ECOG) performance status = 2 or Karnofsky performance status = 70
- •5) Adequate organ function defined by the screening laboratory inclusion listed below and Left Ventricular Ejection Fraction (LVEF) = 45% confirmed by ECHO or MUGA
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 24
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 70
排除标准
- •1) Diagnosis of Primary Mediastinal Large B-cell Lymphoma
- •2) A life threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety or interfere with the absorption or metabolism of ENTO
- •3) Active or symptomatic CNS disease or epidural involvement
- •4) Uncontrolled intercurrent illness including, but not limited to, unstable angina pectoris or psychiatric illness/social situations that would limit compliance with study requirements
- •5) Current/ongoing neuropathy (sensory or motor) Grade > 1 or any history of Grade = 3 neuropathy with prior VCR or chemotherapy exposure (documentation by history is adequate to exclude)
- •6) Contraindication to receive VCR or any planned protocol-specified chemotherapy
- •7) Eligible for autologous stem cell transplant
- •8) History of myelodysplastic syndrome, allogeneic stem cell or solid organ transplantation
- •9) History of any other non-lymphoid malignancy other than the registrational
- •histology or any other non-lymphoid malignancy except for the
- •following: adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate specific antigen for = 1 year prior to the start of study drug, or any other cancer that has been in complete remission without treatment for = 5 years prior to enrollment
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study to investigate the Safety and Efficacy of Entospletinib (GS-9973) in combination with standard of care in adult subjects with Non-Hodgkin Lymphoma (NHL).EUCTR2015-002731-17-ESGilead Sciences, Inc.124
进行中（未招募）
1 期
A Clinical Study to investigate the Safety and Efficacy of Entospletinib (GS-9973) in combination with standard of care in adult subjects with Non-Hodgkin Lymphoma (NHL).EUCTR2015-002731-17-GBGilead Sciences, Inc.10
进行中（未招募）
不适用
A study evaluating the Safety and Efficacy of Entospletinib (GS-9973) in combination with standard of care in adult subjects with Relapsed or Refractory Acute Lymphoid Leukemia (ALL).Relapsed or Refractory Acute Lymphoid Leukemia (ALL)EUCTR2015-002768-18-DEGilead Sciences, Inc.35
进行中（未招募）
1 期
Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options (STARTRK-NG)Pediatric Solid tumors and primary central nervous system (CNS) tumorsMedDRA version: 20.0Level: LLTClassification code: 10025648Term: Malignant mast cell tumors unspecified site extranodal and solid organ sites Class: 10029104CTIS2023-505088-35-00F. Hoffmann-La Roche AG93
进行中（未招募）
1 期
study to evaluate the safety of the study drug, GSK2857916, at different doses and how well it works to treat people with multiple myeloma when taken together with Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B).Relapsed / Refractory Multiple MyelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2017-004689-93-GBGlaxoSmithKline Research & Development Ltd152